Abstract
Background We used patient derived organoids (PDOs) to study the epithelial-specific transcriptional and secretome signatures of the ileum during CD with varying phenotypes to screen for disease profiles and potential druggable targets.
Methods RNA sequencing was performed on isolated intestinal crypts and 3-week-old PDOs derived from ileal biopsies of CD patients (n= 8 B1, inflammatory; n= 8 B2, stricturing disease) and non-IBD controls (n= 13). Differentially expressed (DE) genes were identified by comparing CD vs control, B1 vs B2, and inflamed vs non-inflamed. DE genes were used for computational screening to find candidate small molecules that could potentially reverse B1and B2 gene signatures. The secretome of a second cohort (n= 6 non-IBD controls, n=7 CD; 5 non-inflamed, 2 inflamed) was tested by Luminex using cultured organoid conditioned media.
Results We found a 90% similarity in both the identity and abundance of protein coding genes between PDOs and intestinal crypts (15,554 transcripts of 19,900 genes). DE analysis identified 814 genes among disease group (CD vs non-IBD control), 470 genes different between the CD phenotypes, and 5 FDR significant genes between inflamed and non-inflamed CD. The PDOs showed both similarity and diversity in the levels and types of soluble cytokines and growth factors they released. Perturbagen analysis revealed potential candidate compounds to reverse B2 disease phenotype to B1 in PDOs.
Conclusion PDOs are similar at the transcriptome level with the in vivo epithelium and retain disease-specific gene expression for which we have identified secretome products, druggable targets and corresponding pharmacological agents. Targeting the epithelium could reverse a stricturing phenotype and improve outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support was supported in part by NIH (DK89674) and the Marcus Foundation. JDM was in part supported by a career development award from Crohns and Colitis Foundation CDA#451678. This work was also funded from NIH T32 grant number DK108735-4 for BJN fellowship. Research reported in this publication was supported in part by the Integrated Cellular Imaging shared resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB ID: CR001-IRB00085516 Subra Kugathasan The Emory IRB approved it by the expedited process on 11/9/2020, per 45 CFR 46.110, the Federal Register expeditable categories F(2)a, F(2)b, F(5), F(7), and/or 21 CFR 56.110. This reapproval is effective from 11/9/2020 through 11/8/2021.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing financial interests The authors disclose no conflicts.
Data availability The Gene expression data for all 29 mucosal terminal ileal biopsies from 16 CD patients and 13 non-IBD controls included in this study have been deposited in the Sequence Read Archive (SRA) and are accessible through SRA series accession SUB7687325.
Grant support Financial support was supported in part by NIH (DK89674) and the Marcus Foundation. JDM was in part supported by a career development award from Crohn’s and Colitis Foundation CDA#451678. This work was also funded from NIH T32 grant number DK108735-4 for BJN fellowship. Research reported in this publication was supported in part by the Integrated Cellular Imaging shared resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability
The data is available upon request to the corresponding author
Abbreviations
- (CD)
- Crohn’s disease
- (DE)
- Differentially expressed
- (DEGs)
- Differentially expressed genes
- (FDR)
- False discovery rate correction
- (FC)
- Fold change
- (PDO)
- Patient derived organoids
- (PDGF)
- Platelet-derived growth factor
- (RIN)
- RNA integrity numbers
- (PCA)
- Principle component analysis
- (SRA)
- Sequence Read Archive
- (UC)
- Ulcerative colitis
